{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T10:37:56Z","timestamp":1775471876065,"version":"3.50.1"},"reference-count":38,"publisher":"Academy of Managed Care Pharmacy","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JMCP"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.18553\/jmcp.2025.31.9.900","type":"journal-article","created":{"date-parts":[[2025,8,30]],"date-time":"2025-08-30T09:03:56Z","timestamp":1756544636000},"page":"900-908","source":"Crossref","is-referenced-by-count":1,"title":["Capivasertib cost-effectiveness in treating advanced breast cancer: A US health care perspective"],"prefix":"10.18553","volume":"31","author":[{"given":"Chijioke","family":"Okeke","sequence":"first","affiliation":[{"name":"The Prescription Drug Misuse Education and Research Center, College of Pharmacy, University of Houston, TX"},{"name":"Department of Pharmaceutical Health Outcomes and Policy, College of Pharmacy, University of Houston, TX"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javeria","family":"Khalid","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Health Outcomes and Policy, College of Pharmacy, University of Houston, TX"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. Douglas","family":"Thornton","sequence":"additional","affiliation":[{"name":"The Prescription Drug Misuse Education and Research Center, College of Pharmacy, University of Houston, TX"},{"name":"Department of Pharmaceutical Health Outcomes and Policy, College of Pharmacy, University of Houston, TX"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Moosa","family":"Tatar","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Health Outcomes and Policy, College of Pharmacy, University of Houston, TX"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"7818","reference":[{"key":"r1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21708"},{"issue":"3","key":"r2","first-page":"209","volume":"71","author":"Sung H","year":"2021","journal-title":"CA Cancer J Clin."},{"key":"r3","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16010062"},{"key":"r4","unstructured":"National Institutes of Health; National CancerInstitute. Surveillance, Epidemiology, and End Results Program. Cancer stat facts: Female breast cancer. Accessed February 12, 2024. https:\/\/seer.cancer.gov\/statfacts\/html\/"},{"key":"r5","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2018.19323"},{"key":"r6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1609709"},{"key":"r7","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2021-0668"},{"key":"r8","doi-asserted-by":"publisher","DOI":"10.1016\/j.currproblcancer.2016.09.001"},{"key":"r9","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2016.1897"},{"key":"r10","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21103528"},{"key":"r11","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.34675"},{"key":"r12","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.28.8415"},{"key":"r13","doi-asserted-by":"publisher","DOI":"10.37349\/etat.2022.00096"},{"key":"r14","doi-asserted-by":"publisher","DOI":"10.1186\/1472-6874-8-22"},{"key":"r15","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-023-00604-3"},{"key":"r16","doi-asserted-by":"publisher","DOI":"10.1007\/s11684-020-0795-4"},{"key":"r17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2214131"},{"key":"r18","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2020-1264"},{"key":"r19","doi-asserted-by":"publisher","DOI":"10.1016\/j.breast.2022.03.018"},{"key":"r20","unstructured":"US Food and Drug Administration. FDA approves capivasertib with fulvestrant for breast cancer. Accessed May 10, 2024. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-capivasertib-fulvestrant-breast-cancer"},{"key":"r21","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1495082"},{"key":"r22","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-024-01456-x"},{"key":"r23","doi-asserted-by":"publisher","DOI":"10.1177\/0272989X16670617"},{"key":"r24","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.00137"},{"key":"r25","doi-asserted-by":"publisher","DOI":"10.1159\/000518551"},{"key":"r26","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-018-05099-3"},{"key":"r27","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S284556"},{"key":"r28","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.658747"},{"key":"r29","doi-asserted-by":"crossref","unstructured":"Husereau D, Drummond M, Petrou S, et\u00a0al. Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement. 2013;16(6):713-9. doi:10.3111\/13696998.2013.784591","DOI":"10.3111\/13696998.2013.784591"},{"key":"r30","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2288-11-139"},{"key":"r31","unstructured":"NCCN clinical practice guidelines in Oncology (NCCN guidelines) breast cancer. National Comprehensive Cancer Network. Accessed March 10, 2023. https:\/\/www.nccn.org\/professionals\/physician_gls\/default.aspx#site"},{"key":"r32","unstructured":"Centers for Medicare and Medicaid services. Medicare Part B drug average sale price. 2023. Accessed March 10, 2023. https:\/\/www.cms.gov\/medicare\/payment\/part-b-drugs\/asp-pricing-files"},{"key":"r33","first-page":"173","volume":"8","author":"Rashid N","year":"2016","journal-title":"Breast Cancer (Dove Med Press)"},{"key":"r34","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0196007"},{"key":"r35","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1068463"},{"key":"r36","doi-asserted-by":"publisher","DOI":"10.1007\/s12094-023-03247-w"},{"key":"r37","unstructured":"TreeAge Software, Inc. Generating probabilities from Kaplan Meier survival data. Accessed April 4, 2024. https:\/\/treeage.zendesk.com\/hc\/en-us\/articles\/360018746954-Generating-Probabilities-from-Kaplan-Meier-Survival-Data"},{"key":"r38","doi-asserted-by":"publisher","DOI":"10.1586\/erp.10.65"}],"container-title":["Journal of Managed Care &amp; Specialty Pharmacy"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T09:23:19Z","timestamp":1775467399000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jmcp.org\/doi\/10.18553\/jmcp.2025.31.9.900"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":38,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["10.18553\/jmcp.2025.31.9.900"],"URL":"https:\/\/doi.org\/10.18553\/jmcp.2025.31.9.900","relation":{},"ISSN":["2376-0540","2376-1032"],"issn-type":[{"value":"2376-0540","type":"print"},{"value":"2376-1032","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9]]}}}